KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Share-based Compensation (2016 - 2025)

Teladoc Health's Share-based Compensation history spans 12 years, with the latest figure at $15.9 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 42.08% year-over-year to $15.9 million; the TTM value through Dec 2025 reached $80.4 million, down 44.9%, while the annual FY2025 figure was $80.4 million, 44.9% down from the prior year.
  • Share-based Compensation for Q4 2025 was $15.9 million at Teladoc Health, down from $17.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $86.3 million in Q1 2021 and bottomed at $15.9 million in Q4 2025.
  • The 5-year median for Share-based Compensation is $48.8 million (2022), against an average of $47.4 million.
  • The largest YoY upside for Share-based Compensation was 371.2% in 2021 against a maximum downside of 85.13% in 2021.
  • A 5-year view of Share-based Compensation shows it stood at $61.6 million in 2021, then dropped by 17.63% to $50.8 million in 2022, then dropped by 7.75% to $46.8 million in 2023, then crashed by 41.33% to $27.5 million in 2024, then plummeted by 42.08% to $15.9 million in 2025.
  • Per Business Quant, the three most recent readings for TDOC's Share-based Compensation are $15.9 million (Q4 2025), $17.0 million (Q3 2025), and $22.3 million (Q2 2025).